Bybit has introduced new perpetual contracts for Orochi Network (OROCHI) and MEET48 (IDOL) in its innovation zone as of November 13. These contracts are denominated in USDT and offer different maximum leverage options: 50x for OROCHI and 20x for IDOL. This move expands trading options for investors interested in these digital assets, allowing for potentially higher returns through leverage. Traders should consider the risks associated with high leverage before participating.
Bybit's listing of Orochi Network (OROCHI) and MEET48 (IDOL) perpetual contracts offers new trading options. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Nov 13, 2026 17:21 WIB: out of 50 major cryptocurrencies priced on Pluang, 12 rose and 37 fell today. Notable movers include SXP (Solar) down 46.27% at Rp37 with a typical hold time of 94 days, BAL (Balancer) up 11.14% at Rp16,297 with a typical hold time of 85 days, and ONE (Harmony) down 8.41% at Rp27 with a typical hold time of 153 days and Pluang order activity showing 40% sell and 60% buy.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
